ClinicalTrials.gg
RecruitingNCT07839247Updated Nov 10, 2026

Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL

A Phase 2 interventional study of Zanubrutinib and Lenalidomide in Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib and Lenalidomide, sponsored by Xiaohui Ren. Recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xiaohui Ren · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Study summary

This is a prospective, single-arm, phase II clinical study evaluating the efficacy and safety of Zanubrutinib (a BTK inhibitor) plus Lenalidomide (an immunomodulatory drug) in frail elderly patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The study plans to enroll 33 patients who are aged ≥ 70 years and classified as frail, a population for whom standard first-line treatment regimens, high-dose methotrexate-based chemotherapy, may be "unfit". This study includes screening phase, induction phase, consolidation phase and maintenance phase. The screening period is defined as within 1 week prior to the first dose. During induction, participants will receive Zanubrutinib 160 mg orally twice daily continuously and Lenalidomide 25 mg orally once daily on days 1-21 of each 28-day cycle for three cycles. Participants who achieve a partial response (PR) or complete response (CR) after induction will receive three additional 28-day consolidation cycles of the same regimen. Participants who achieve a CR after consolidation will continue maintenance treatment with Zanubrutinib and Lenalidomide until disease progression. Treatment response will be assessed throughout the study using the International Primary CNS Lymphoma Collaborative Group (IPCG) criteria and assessed every 3 months. The primary endpoint is the complete response rate (CRR) at the end of induction therapy. Secondary endpoints include overall response rate (ORR) at the end of induction therapy, CRR and ORR at the end of consolidation therapy, One-year and two-year progression-free survival (PFS) rates, Duration of response (DOR), overall survival (OS), adverse event (AE) and serious adverse event (SAE). Exploratory liquid-biopsy analyses will be performed to evaluate treatment response and prognosis.

02

Conditions studied

  • Primary Central Nervous System Lymphoma (PCNSL)
  • Zanubrutinib
  • Lenalidomide
  • Frail Elderly

Keywords

  • primary central nervous system lymphoma
  • elderly
  • frail
  • zanubrutinib
  • lenalidomide
03

In context

Lead sponsor

Xiaohui Ren is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 70 years.
  2. patients classified as "Frail"according to the simplified Geriatric Assessment (sGA):

    --ADL ≤ 4 residual functions, or

    • IADL ≤ 5 residual functions, or
    • CIRS: ≥ 1 comorbidity of grade 3-4 or > 8 comorbidities of grade 2, or
    • Age ≥ 80 years with "UNFIT" profile "UNFIT" profile: ADL = 5 residual functions or IADL = 6-7 residual functions, or CIRS: 0 comorbidity of grade 3-4 and 5-8 comorbidities of grade 2.
  3. Voluntary provision of written .
  4. (ECOG) performance status of 0-3.
  5. Considered able to safely undergo lumbar puncture.
  6. of ≥ 3 months, as judged by the investigator.
  7. confirmed diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS).
  8. Hematologic function: ≥ 1.5 x 10\^9/L, ≥ 90 g/L, and count ≥ 80 x 10\^9/L.
  9. Hepatic function: serum total ≤ 1.5 x the (ULN), and serum and aspartate aminotransferase ≤ 2.5 x ULN.
  10. Renal function: ≥ 30 mL/min, as estimated using the Cockcroft-Gault formula, or serum creatinine ≤ 1.5 x ULN.
  11. Coagulation function: (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN.
  12. Female participants of must have a negative pregnancy test within 7 days before the first dose and agree not to donate oocytes for reproductive purposes throughout the treatment and follow-up periods. Their male sexual partners must use condoms during sexual intercourse.
  13. Male participants with female partners of childbearing potential must use condoms during sexual intercourse throughout the study and refrain from donating or cryopreserving sperm during this period.
  14. Participants with stable and adequately controlled comorbidities may be enrolled, including those with hypertension (blood pressure ≤ 160/100 mmHg), type 2 diabetes mellitus ( ≤ 8%), or mild coronary artery disease without myocardial infarction within the preceding 6 months.

Exclusion criteria

Exclusion Criteria

  1. Any disease or condition that may impair drug absorption (e.g., active inflammatory gastrointestinal disease, active gastric ulcer, chronic diarrhea, dysphagia, prior gastrectomy, gastroparesis, or short bowel syndrome).
  2. Known to zanubrutinib, lenalidomide, or any contained in either drug.
  3. Active bleeding within 1 month before treatment; a need for therapeutic anticoagulation during the study (e.g., warfarin or other vitamin K antagonists); or any condition associated with an increased risk of bleeding or coagulopathy (e.g., high-risk esophageal varices or active ulcer disease).
  4. High risk of thrombosis.
  5. Concurrent participation in another interventional clinical study (participation in noninterventional observational studies is permitted).
  6. Major surgery within 4 weeks before treatment or an incompletely healed surgical incision.
  7. Treatment with systemic within 4 weeks before treatment.
  8. Another active or a history of another malignancy within 5 years before the initiation of study treatment, except for malignancies adequately treated with curative intent, such as basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, or ductal carcinoma in situ of the breast.
  9. Receipt of any vaccine, including but not limited to a vaccine against COVID-19, influenza, pneumonia, herpes zoster, or , within 4 weeks before the first dose.
  10. Requirement for treatment with a moderate or strong /5 inhibitor or inducer within 2 weeks before the first dose or during the study;
  11. Stroke or intracranial hemorrhage within 6 months before the first dose.
  12. Known liver disease, including but not limited to alcoholic liver disease, cirrhosis, active hepatitis B virus (HBV) infection (detectable HBV DNA), active virus (HCV) infection (detectable HCV RNA), or other active hepatitis. Participants with HBV DNA below the limit of detection or cured HCV infection are not excluded. Participants with HBV or HCV infection may be enrolled after antiviral therapy, provided that HBV DNA is below the limit of detection or HCV RNA is undetectable, as applicable.
  13. Active syphilis.
  14. (HIV) infection
  15. Epstein-Barr virus (EBV) infection
  16. An active infection requiring systemic treatment or unexplained fever with a body temperature ≥ 38.5℃ within 1 week before treatment;
  17. Any of the following cardiac or cardiovascular criteria:

(1)A heart rate- interval calculated using Fridericia's formula (QTcF) > 470 ms in females or > 450 ms in males, or other risk factors for QT-interval prolongation or arrhythmic events (e.g., hypokalemia or a personal or family history of long QT syndrome); (2)A arrhythmia or other cardiovascular disease requiring clinical intervention, including but not limited to acute myocardial infarction, unstable angina, or coronary artery bypass grafting within 6 months before treatment; congestive heart failure of (NYHA) class II or higher; (LVEF) \< 50%; hypertension not controlled with medication (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg); atrial fibrillation of European Heart Rhythm Association (EHRA) class ≥ 2b; or primary cardiomyopathy.

18. Prior organ transplantation or stem cell transplantation.

19. Prior or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, or radiation pneumonitis considered by the investigator to render the patient unsuitable for the study.

20. An disease requiring systemic treatment within the previous 2 years.

21. Incomplete clinical data (e.g., no pathology report or inability to undergo MRI or PET/CT assessment).

22. Pregnant (positive pregnancy test before dosing) or breastfeeding.

23. Any other disease, psychiatric disorder, metabolic abnormality, physical examination finding, or clinically significant laboratory abnormality that, in the investigator's judgment, may compromise the participant's adherence to the study requirements, expose the participant to an unacceptable risk, interfere with the interpretation of the study results, or otherwise render the participant unsuitable for treatment with the study drugs.

24. Any other circumstance that, in the investigator's judgment, renders the patient unsuitable for participation in the study.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Zanubrutinib plus lenalidomide

    Drug: Zanubrutinib · Drug: Lenalidomide

Interventions

  • Zanubrutinib will be administered orally at 160 mg twice daily. Each treatment cycle will last 28 days. Induction phase: Induction treatment will consist of three cycles. Consolidation phase: Patients who achieve a partial response (PR) or complete response (CR) after induction treatment will proceed to consolidation treatment. Consolidation treatment will consist of three cycles. Maintenance phase: Patients who achieve a CR after consolidation will proceed to maintenance treatment.

  • Lenalidomide will be administered orally at 25 mg once daily on days 1-21 of each cycle. Each treatment cycle will last 28 days. Induction phase: Induction treatment will consist of three cycles. Consolidation phase: Patients who achieve a partial response (PR) or complete response (CR) after induction treatment will proceed to consolidation treatment. Consolidation treatment will consist of three cycles. Maintenance phase: Patients who achieve a CR after consolidation will proceed to maintenance treatment.

06

What researchers measure

Primary outcomes

  1. CRR

    complete response rate

    Time frame: From the first day of treatment to the completion of induction treatment (3 months)

Secondary outcomes

  1. CRR

    complete response rate

    Time frame: From the first day of treatment to the completion of consolidation treatment (6 months)

  2. ORR

    overall response rate

    Time frame: From the first day of treatment to the completion of induction treatment (3 months)

  3. ORR

    overall response rate

    Time frame: From the first day of treatment to the completion of consolidation treatment (6 months)

  4. PFS

    progression-free survival

    Time frame: 1-year and 2-year PFS rates, and the time interval from the start of treatment to tumor progression or death from any cause (up to 24 months).

  5. DOR

    Duration of response

    Time frame: Time from documentation of tumor response (CR or PR) to disease progression or death (up to 24 months).

  6. OS

    overall survival

    Time frame: The percentage of surviving patients out of the total number of included patients (specifically assessed as 1- and 2-year OS rate in study objectives) (up to 24 months).

  7. AE

    adverse event

    Time frame: From the first day of treatment until 30 days after the last treatment (up to 24 months)

  8. SAE

    serious adverse event

    Time frame: from the first day of treatment until 30 days after the last treatment (up to 24 months)

Other outcomes

  1. CSF/PLA ctDNA and cfRNA

    Changes in cerebrospinal fluid and plasma ctDNA and cfRNA

    Time frame: From baseline through the end of induction and consolidation treatment, during maintenance treatment, and at disease progression (up to 24 months).

  2. Change From Baseline in EORTC QLQ-C30 Scale Scores

    Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, version 3.0 (EORTC QLQ-C30). The questionnaire generates a global health status/quality-of-life score, five functional scale scores (physical, role, emotional, cognitive, and social functioning), three symptom scale scores (fatigue, nausea/vomiting, and pain), and six single-item scores (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each scale or item score is linearly transformed to a range of 0 to 100 according to the EORTC scoring manual. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life, whereas higher scores on the symptom scales and single-item measures indicate greater symptom burden or problems. Change from baseline is calculated as the post-baseline score minus the baseline score.

    Time frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months

  3. Change From Baseline in EORTC QLQ-BN20 Scale and Single-Item Scores

    Brain tumor-related symptoms and problems will be assessed using the 20-item European Organisation for Research and Treatment of Cancer Brain Neoplasm Module (EORTC QLQ-BN20), administered together with the EORTC QLQ-C30. The instrument generates four multi-item scale scores (future uncertainty, visual disorder, motor dysfunction, and communication deficit) and seven single-item scores (headache, seizures, drowsiness, hair loss, itchy skin, weakness of the legs, and bladder control). Each score is linearly transformed to a range of 0 to 100 according to the EORTC scoring manual. Higher scores indicate greater symptom burden or more severe problems. Change from baseline is calculated as the post-baseline score minus the baseline score.

    Time frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months

  4. Change From Baseline in Mini-Mental State Examination Total Score

    Global cognitive function will be assessed using the Mini-Mental State Examination (MMSE). The MMSE evaluates orientation, registration, attention and calculation, recall, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores indicating better cognitive function and lower scores indicating greater cognitive impairment. Change from baseline is calculated as the post-baseline total score minus the baseline total score.

    Time frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared because the dataset contains sensitive clinical and genomic information, and the informed consent does not cover public data sharing.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 24, 2026
StartActual
Sep 25, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Aug 1, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
Deparment of neurosurgery, Beijing tiantan hospital is now Recruiting
Sep 28, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • Addedother outcomeChange From Baseline in EORTC QLQ-C30 Scale ScoresTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months
  • Addedother outcomeChange From Baseline in EORTC QLQ-BN20 Scale and Single-Item ScoresTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months
  • Addedother outcomeChange From Baseline in Mini-Mental State Examination Total ScoreTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months
Sep 28, 2026
Show all 2 updates
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  2. Sep 28, 2026
    Not yet recruiting→Recruiting
    Deparment of neurosurgery, Beijing tiantan hospital is now Recruiting
    Secondary outcomes 3 added
    What changed in the outcomes
    • Addedother outcomeChange From Baseline in EORTC QLQ-C30 Scale ScoresTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months
    • Addedother outcomeChange From Baseline in EORTC QLQ-BN20 Scale and Single-Item ScoresTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months
    • Addedother outcomeChange From Baseline in Mini-Mental State Examination Total ScoreTime frame: Baseline; end of Cycle 3 (approximately Week 12); end of Cycle 6 (approximately Week 24); and every 3 months thereafter until disease progression or treatment discontinuation, up to 24 months

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07839247
Lead sponsor
Xiaohui Ren
Responsible party
Xiaohui Ren (Deparment of neurosurgery, Beijing tiantan hospital, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Sep 24, 2026
Start date
Sep 25, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Xiaohui Ren, MD
Contact
xiaohuiren@mail.ccmu.edu.cn/xiaohuiren@aliyun.com
+86-010-59975567
Haoyi Li, MD
Contact
lee_627269051@163.com
+86-010-59975567

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Lenalidomide

Start the discussion